

**ASX Announcement**

17 September 2024

**Cleansing Notice – Section 708A (5)(e) of the Corporations Act 2001**

BCAL Diagnostics Limited gives this notice pursuant to Section 708A(5)(e) of the Corporations Act in relation to the issue of 869,565 shares as set out in the Appendix 2A dated 17 August 2024.

The Company issued 869,565 shares under LR 7.1 to advisers at a price of \$0.115 per share as outlined in the Appendix 2A, without disclosure, under Part 6D.2 of the Corporations Act.

The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
- (b) section 674 of the Corporations Act.

As at the date of this notice, there is no information to be disclosed that is “excluded information” within the meaning of section 708A(7) and 708A (8) of the Corporations Act.

This announcement has been approved by the Company Secretary.

Yours faithfully

A handwritten signature in black ink, appearing to read "Guy Robertson", is written over a faint, large watermark that says "For persons".

Guy Robertson  
Company Secretary



### About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>

For personal use